The CDC’s changes threaten to cut vaccine sales for makers including Pfizer, Moderna, Merck and more, but a legal expert ...
European regulators have approved Moderna Inc.’s novel combination flu and Covid shot, handing a victory to the embattled ...
Management provided a 2026 adjusted total revenue target of $230 million to $270 million, including $35 million to $45 million of Nuvaxovid product sales under existing orders, $40 million to $50 ...
Commissioner Marty Makary defended his agency's position and record on mRNA vaccines, days after it changed course and agreed ...
Moderna has announced that the FDA will initiate the review of its seasonal influenza vaccine candidate, mRNA-1010.
Dr. Vinay Prasad, vaccine chief at the the U.S. Food and Drug Administration (FDA), said in an internal memo in November that ...
6don MSN
US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost
By Ahmed Aboulenein WASHINGTON, Feb 23 (Reuters) - U.S. Food and Drug Administration Commissioner Marty Makary on Monday ...
In August last year, the Health Department cut around $500 million in mRNA research funding, with Health Secretary Robert F.
Pfizer’s Albert Bourla put it more bluntly in Davos last month, saying it’s a “different world when you start discussing ...
Q4 2025 Earnings Call February 26, 2026 8:30 AM ESTCompany ParticipantsLuis Sanay - Vice President of Investor RelationsJohn Jacobs ...
Covid vaccines are once again on the agenda for the Centers for Disease Control and Prevention’s vaccine advisory panel.
The stock dropped in after-hours trading as investors remained anxious about the potential of AI disrupting traditional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results